Immuno-Isolation in cancer gene therapyCIRONE, Pasquale; POTTER, Murray; HIRTE, Hal et al.Current gene therapy. 2006, Vol 6, Num 2, pp 181-191, issn 1566-5232, 11 p.Article

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)HEINRICH, Michael C; MCARTHUR, Grant A; DIRNHOFER, Stephan et al.Journal of clinical oncology. 2006, Vol 24, Num 7, pp 1195-1203, issn 0732-183X, 9 p.Article

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer : A Trial of the California, Chicago, and Princess Margaret Hospital Phase II ConsortiaGARCIA, Agustin A; HIRTE, Hal; SCUDDER, Sidney et al.Journal of clinical oncology. 2008, Vol 26, Num 1, pp 76-82, issn 0732-183X, 7 p.Article

A multinomial phase II study of lonafamib (SCH 66336) in patients with refractory urothelial cancerWINQUIST, Eric; MOORE, Malcolm J; SEYMOUR, Lesley et al.Urologic oncology. 2005, Vol 23, Num 3, pp 143-149, issn 1078-1439, 7 p.Article

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumorsDIAZ-PADILLA, Ivan; HIRTE, Hal; RAZAK, Albiruni A. R et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1182-1191, issn 0167-6997, 10 p.Article

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancerCAMPOS, Susana; HAMID, Oday; CHARBONNEAU, Claudie et al.Journal of clinical oncology. 2005, Vol 23, Num 24, pp 5597-5604, issn 0732-183X, 8 p.Article

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumoursMACKAY, Helen J; HIRTE, Hal; PAN, James et al.European journal of cancer (1990). 2010, Vol 46, Num 9, pp 1573-1579, issn 0959-8049, 7 p.Article

A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced CancerCHI, Kim N; SIU, Lillian L; DONGSHENG TU et al.Clinical cancer research. 2008, Vol 14, Num 3, pp 833-839, issn 1078-0432, 7 p.Article

A phase II trial of JM-216 in cervical cancer: An NCIC CTG studyTRUDEAU, Marc; STUART, Gavin; HIRTE, Hal et al.Gynecologic oncology (Print). 2002, Vol 84, Num 2, pp 327-331, issn 0090-8258Article

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumorsCHU, Quincy S; SANGHA, Randeep; HOTTE, Sebastien J et al.Investigational new drugs. 2014, Vol 32, Num 6, pp 1226-1235, issn 0167-6997, 10 p.Article

Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. CommentaryTOWNSLEY, Carol A; POND, Gregory R; CHRISTIAN, Michaele C et al.Clinical cancer research. 2006, Vol 12, Num 7, issn 1078-0432, 1956-1957, 2141-2149 [11 p.], 1Article

An optimized clinical regimen for the oncolytic virus PV701HOTTE, Sébastien J; LORENCE, Robert M; HIRTE, Hal W et al.Clinical cancer research. 2007, Vol 13, Num 3, pp 977-985, issn 1078-0432, 9 p.Article

Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted AgentsPOND, Gregory R; SIU, Lillian L; MOORE, Malcolm et al.Journal of clinical oncology. 2008, Vol 26, Num 8, pp 1324-1330, issn 0732-183X, 7 p.Article

Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trialTRAN, Ben; BROWN, Andrew M. K; FERRETTI, Vincent et al.International journal of cancer (Print). 2013, Vol 132, Num 7, pp 1547-1555, issn 0020-7136, 9 p.Article